SCHEMBL20775334

SCHEMBL20775334

O=c1[nH]c2ccc(-c3ccnc(Cl)c3)cc2[nH]1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 2/20 0.65
PDE3A Q14432 2/20 0.65
GRIA1 P42261 10/20 0.54
CACNG8 Q8WXS5 9/20 0.54
IDO1 P14902 2/20 0.45
CCNC P24863 1/20 0.43
CDK8 P49336 1/20 0.43
CDC7 O00311 1/20 0.43
ROCK2 O75116 1/20 0.43
MAP4K4 O95819 1/20 0.43
CDK2 P24941 1/20 0.43
MAPKAPK2 P49137 1/20 0.43
GSK3B P49841 1/20 0.43
HIPK2 Q9H2X6 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.43
GRIK1 P39086 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA3 P42263 1/20 0.41
GRIA4 P48058 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30832781 1.00 PDE3B (0.65) PDE3BPDE3AGRIA1CACNG8IDO1
SCHEMBL31192609 0.79 PDE3B (1.00) PDE3BPDE3AGRIA1CACNG8CDC7
SCHEMBL4027001 0.75 IDO1 (0.55) IDO1CCNCCDK8CDC7ROCK2
SCHEMBL18190621 0.74 GRIA1 (0.62) PDE3BPDE3AGRIA1CACNG8CDC25A
SCHEMBL18190673 0.74 PDE3B (0.65) PDE3BPDE3AGRIA1CACNG8CDC7
SCHEMBL28528908 0.72 GRIA1 (0.65) PDE3BPDE3AGRIA1CACNG8
SCHEMBL22191125 0.71 PDE3B (0.57) PDE3BPDE3AGRIA1CACNG8IDO1
SCHEMBL31240651 0.71 JAK2 (0.67) CDC7ROCK2MAP4K4CDK2CLK4
SCHEMBL18632516 0.71 PDE3B (0.67) PDE3BPDE3AGRIA1CACNG8MAP4K4
SCHEMBL18190488 0.70 GRIA1 (0.77) PDE3BPDE3AGRIA1CACNG8GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3679027-A1 DIHYDROBENZIMIDAZOLONES C4 Therapeutics, Inc. (US) 2020-07-15 EP claimed
WO-2019043217-A1 DIHYDROBENZIMIDAZOLONES F. HOFFMANN-LA ROCHE AG (CH) 2019-03-07 WO claimed
US-12365681-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2025-07-22 US disclosed
CN-118206529-A Dihydrobenzimidazolone C4医药公司 2024-06-18 CN disclosed
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-04-04 US disclosed
CN-111315735-B Dihydrobenzimidazolone C4医药公司 2024-03-08 CN disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2022-09-15 US disclosed
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2022-09-15 US disclosed
US-11254672-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2022-02-22 US disclosed
US-11254672-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2022-02-22 US disclosed
EP-3679027-A1 DIHYDROBENZIMIDAZOLONES C4 Therapeutics, Inc. (US) 2020-07-15 EP disclosed
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 US disclosed
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 US disclosed
CN-111315735-A Dihydrobenzimidazolones C4医药公司 2020-06-19 CN disclosed
WO-2019043217-A1 DIHYDROBENZIMIDAZOLONES F. HOFFMANN-LA ROCHE AG (CH) 2019-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 PDE3B 4080/4885PDE3A 4172/4885GRIA1 1196/4885
US-12365681-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 PDE3B 4080/4885PDE3A 4172/4885GRIA1 1196/4885
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 PDE3B 4080/4885PDE3A 4172/4885GRIA1 1196/4885
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 PDE3B 4080/4885PDE3A 4172/4885GRIA1 1196/4885
US-11787802-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 PDE3B 4080/4885PDE3A 4172/4885GRIA1 1196/4885
US-11254672-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 PDE3B 4080/4885PDE3A 4172/4885GRIA1 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.